DK1701722T3 - N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt - Google Patents
N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresaltInfo
- Publication number
- DK1701722T3 DK1701722T3 DK05817697T DK05817697T DK1701722T3 DK 1701722 T3 DK1701722 T3 DK 1701722T3 DK 05817697 T DK05817697 T DK 05817697T DK 05817697 T DK05817697 T DK 05817697T DK 1701722 T3 DK1701722 T3 DK 1701722T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzamidine
- pentoxy
- thiazol
- phenoxy
- isopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20040096390 | 2004-11-23 | ||
PCT/KR2005/003934 WO2006057501A1 (en) | 2004-11-23 | 2005-11-22 | N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1701722T3 true DK1701722T3 (da) | 2010-01-11 |
Family
ID=36498212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05817697T DK1701722T3 (da) | 2004-11-23 | 2005-11-22 | N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt |
Country Status (19)
Country | Link |
---|---|
US (2) | US20070254930A1 (da) |
EP (2) | EP1701722B1 (da) |
JP (2) | JP4774053B2 (da) |
KR (2) | KR100716389B1 (da) |
CN (3) | CN1905871B (da) |
AT (1) | ATE445397T1 (da) |
AU (2) | AU2005300239B2 (da) |
BR (2) | BRPI0514386B8 (da) |
CA (2) | CA2585003C (da) |
DE (1) | DE602005017118D1 (da) |
DK (1) | DK1701722T3 (da) |
ES (1) | ES2333739T3 (da) |
HK (1) | HK1094530A1 (da) |
IL (2) | IL180985A (da) |
NZ (1) | NZ555725A (da) |
PT (1) | PT1701722E (da) |
RU (1) | RU2361867C2 (da) |
WO (2) | WO2006057507A1 (da) |
ZA (2) | ZA200700485B (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1773333A4 (en) * | 2004-07-05 | 2010-04-21 | Dong Wha Pharm Co Ltd | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASES |
KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
PT1701722E (pt) * | 2004-11-23 | 2009-12-10 | Dong Wha Pharm Co Ltd | Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico |
DE602008004337D1 (de) | 2007-04-19 | 2011-02-17 | Dong Wha Pharm Co Ltd | 2-ETHANSULFONSÄURESALZ AUS N- HYDROXY-4-ä5-Ä4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXYÜPENTOXYü BENZAMIDIN, VERFAHREN ZU SEINER HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT |
JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
JP6292744B2 (ja) * | 2012-09-19 | 2018-03-14 | 富士カプセル株式会社 | 医薬品組成物 |
EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE |
PL3524595T3 (pl) | 2014-08-28 | 2022-10-31 | Eisai R&D Management Co., Ltd. | Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania |
SI3263106T1 (sl) | 2015-02-25 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Postopek zatiranja grenkobe derivata kinolina |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
MX2017013896A (es) | 2015-04-28 | 2018-03-15 | Astellas Pharma Inc | Composicion farmaceutica para administracion oral. |
MX2017015896A (es) | 2015-06-16 | 2018-08-09 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
BR112020003380A2 (pt) * | 2017-08-18 | 2020-08-25 | Abbvie Inc. | formulações farmacêuticas para o tratamento de endometriose, miomas uterinos, síndrome do ovário policístico ou adenomiose |
KR102276547B1 (ko) * | 2020-09-04 | 2021-07-13 | 주식회사유한양행 | 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
EP0379579A4 (en) * | 1988-02-03 | 1991-01-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pharmaceutical composition having improved releasability |
PA8441701A1 (es) * | 1996-11-26 | 2000-05-24 | Pfizer | Sales dimesilato de los ligandos del neuropeptido y |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
CN1572882A (zh) * | 1999-10-28 | 2005-02-02 | 三共株式会社 | 苯甲脒衍生物 |
KR100454767B1 (ko) * | 2001-07-19 | 2004-11-03 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
KR100789567B1 (ko) * | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
CA2495886C (en) * | 2002-03-06 | 2011-05-03 | Lifizz, Inc. | Effervescent compositions comprising bisphosphonates and methods related thereto |
CA2482382A1 (en) * | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
WO2003101431A1 (en) | 2002-06-04 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
CN100342860C (zh) * | 2003-03-18 | 2007-10-17 | 兴和株式会社 | 抗酸剂组合物 |
PT1701722E (pt) * | 2004-11-23 | 2009-12-10 | Dong Wha Pharm Co Ltd | Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico |
-
2005
- 2005-11-22 PT PT05817697T patent/PT1701722E/pt unknown
- 2005-11-22 CN CN2005800017444A patent/CN1905871B/zh active Active
- 2005-11-22 WO PCT/KR2005/003950 patent/WO2006057507A1/en active Application Filing
- 2005-11-22 CA CA2585003A patent/CA2585003C/en not_active Expired - Fee Related
- 2005-11-22 US US11/577,469 patent/US20070254930A1/en not_active Abandoned
- 2005-11-22 EP EP05817697A patent/EP1701722B1/en active Active
- 2005-11-22 AU AU2005300239A patent/AU2005300239B2/en active Active
- 2005-11-22 DE DE602005017118T patent/DE602005017118D1/de active Active
- 2005-11-22 CA CA2552766A patent/CA2552766C/en active Active
- 2005-11-22 JP JP2007523495A patent/JP4774053B2/ja active Active
- 2005-11-22 RU RU2007123614/04A patent/RU2361867C2/ru active
- 2005-11-22 JP JP2007542909A patent/JP4773456B2/ja not_active Expired - Fee Related
- 2005-11-22 AU AU2005307994A patent/AU2005307994B2/en not_active Ceased
- 2005-11-22 NZ NZ555725A patent/NZ555725A/en unknown
- 2005-11-22 AT AT05817697T patent/ATE445397T1/de active
- 2005-11-22 EP EP05821036A patent/EP1814593A4/en not_active Withdrawn
- 2005-11-22 KR KR1020050111543A patent/KR100716389B1/ko active IP Right Review Request
- 2005-11-22 KR KR1020050111779A patent/KR101047042B1/ko not_active IP Right Cessation
- 2005-11-22 CN CN2009101666678A patent/CN101693029B/zh not_active Expired - Fee Related
- 2005-11-22 WO PCT/KR2005/003934 patent/WO2006057501A1/en active Application Filing
- 2005-11-22 ES ES05817697T patent/ES2333739T3/es active Active
- 2005-11-22 BR BRPI0514386A patent/BRPI0514386B8/pt active IP Right Grant
- 2005-11-22 US US10/584,984 patent/US20090176846A1/en not_active Abandoned
- 2005-11-22 DK DK05817697T patent/DK1701722T3/da active
- 2005-11-22 BR BRPI0517396-5A patent/BRPI0517396A/pt not_active IP Right Cessation
- 2005-11-22 CN CN200580038889A patent/CN100574756C/zh not_active Expired - Fee Related
-
2007
- 2007-01-17 ZA ZA200700485A patent/ZA200700485B/en unknown
- 2007-01-25 IL IL180985A patent/IL180985A/en active IP Right Grant
- 2007-02-08 HK HK07101468.4A patent/HK1094530A1/xx unknown
- 2007-04-18 IL IL182647A patent/IL182647A/en not_active IP Right Cessation
- 2007-05-24 ZA ZA200704236A patent/ZA200704236B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1701722T3 (da) | N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt | |
PE20070351A1 (es) | N-[2-[haloalcoxi)fenil]heteroarilcarboxamidas fungicidas | |
UA92354C2 (en) | Amino acid salts of rosiglitazone | |
CY1107238T1 (el) | Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης | |
JP2010529147A5 (da) | ||
TW200637822A (en) | Process for the preparation of a 2-pyridylethylcarboxamide derivative | |
MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
TW200633981A (en) | Process for the preparation of a 2-ethylaminopyridine derivative | |
DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
WO2011141933A3 (en) | Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts | |
WO2011021214A3 (en) | Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate | |
ATE414080T1 (de) | Synthese von antidiabetischen rosiglitazonderivaten | |
BRPI0910761A2 (pt) | compostos tendo atividade antagonista de receptores npy y5 e composições farmacêuticas compreendendo os mesmos | |
NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner | |
MX2019007327A (es) | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. | |
FR2894578B1 (fr) | Derives heterocycliques, leur preparation et leur application en therapeutique. | |
BRPI0607085A2 (pt) | derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes | |
WO2008133128A1 (ja) | 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 | |
WO2009012201A3 (en) | Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides | |
NZ598754A (en) | Therapeutic agent for anxiety disorders | |
WO2005012273A3 (en) | Process for the preparation of substituted thiazoles | |
EP2146974A4 (en) | SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT | |
WO2019152546A3 (en) | Salt forms of organic compound | |
WO2005021542A3 (en) | Process for the preparation of pioglitazone | |
EA200300230A1 (ru) | Тартратная соль производного тиазолидиндиона |